苏文杰 (2) 0000 01 今年初，以DeepSeek为代表的一系列科技进展，一度引发中国资产价值重估。对于当前中国科技股的 表现，苏文杰仍然持乐观态度。 他表示："在科技股中已经有些细分板块表现得非常亮眼。硬件方面，我们比较关注自主可控相关行 业，半导体是一个很好的例子。此外，鉴于中国、日本和韩国都有望在接下来的50年间缩减大量的劳动 力密集型产业，因此人形机器人或者自动化生产相关板块会涌现巨大的机遇。" 软件方面，现阶段苏文杰更关注AI模型发展中能够提升生产效率的方向。他解释道，类似于移动互联 网，AI大模型同样可以划分为三个发展阶段：第一阶段是部署开发相应的基础设施，包括数据中心、 半导体设备等；第二阶段主要关注产品和服务开发的效能提升，即增加生产效率；第三阶段，将会有一 些头部公司取得突破性发展，进一步推动技术的大幅进步。 ◎记者 汪友若 "外国投资者对于中国市场的信心正在恢复，部分已经回到中性的看法，有些则已经重新调整为高配。 我仍然看好中国市场的表现。在亚太地区内，我们认为中国和印度市场都将维持上升的态势。"日前， 摩根大通亚太区股票研究部主管苏文杰（James Sullivan）在接受上海证 ...

Company Overview - Company is a global metal mining giant focused on upstream metal resources, operating internationally with headquarters in Melbourne, Australia [1] - The company has undergone two major transformations since its listing in Hong Kong in 1994, including the acquisition of MMG in 2010 and the purchase of the Las Bambas copper mine in 2014, significantly enhancing its resource strength [1] - In 2024, the company completed the acquisition of the Khoemacau copper mine in Botswana, adding a key copper asset to its portfolio, which now includes five overseas mines (3 copper and 2 zinc) [1] Financial Performance - Copper is the core metal, contributing significantly to revenue, with copper products generating $3.308 billion in revenue in 2024, accounting for 73.86% of total revenue [2] - Las Bambas mine alone contributed $2.978 billion in revenue, representing 66.48% of total revenue and $1.594 billion in EBITDA, which is 77.82% of the company's EBITDA [2] - The company achieved a net profit attributable to shareholders of $162 million in 2024, a substantial increase of 1699% year-on-year, primarily driven by strong performance from Las Bambas and the acquisition of Khoemacau [2] Production Outlook - Las Bambas is expected to return to normal operations in 2024, with copper production projected at 322,900 tons, and production guidance for 2025 set at 360,000 to 400,000 tons [3] - Kinsevere is transitioning from oxide to sulfide ore, with 2024 copper production expected at 45,000 tons and guidance for 2025 set at 63,000 to 69,000 tons, with a potential reduction in C1 costs [3] - Khoemacau, acquired in 2024, is projected to produce 31,000 tons of copper in 2024, with guidance for 2025 set at 43,000 to 53,000 tons, and expansion plans aiming for an annual capacity of 130,000 tons by 2028 [3] Industry Insights - The copper industry is experiencing tight supply and demand dynamics, with capital expenditures declining and resource depletion creating supply constraints [4] - The recent drop in copper prices is expected to have absorbed pessimistic demand forecasts, with downstream consumption likely to grow as prices stabilize [4] - The company is well-positioned to benefit from rising copper prices due to the growth potential of its three major copper projects and an improving financial structure [4] Profit Forecast and Investment Recommendation - The company is expected to see significant profit growth, with net profits projected at $420 million, $640 million, and $750 million for 2025, 2026, and 2027 respectively, reflecting year-on-year increases of 162%, 50%, and 18% [4] - Earnings per share (EPS) are forecasted to be $0.03, $0.05, and $0.06 for the same years, corresponding to price-to-earnings (PE) ratios of 10.6, 7.1, and 6.0 [4] - Given the company's resource advantages and growth potential, a target price of HKD 3.5 is set, with an initial "buy" rating based on a valuation of 8.5 times the 2026 earnings [4]

同时，公募基金自购热情持续升温。5月27日，上海东方证券资产管理有限公司发布公告称，将于近期 运用自有资金1000万元投资旗下产品东方红核心价值混合。近期，招商证券资管、安信基金、富国基金 等也宣布自购旗下产品。Choice数据显示，截至5月28日，今年以来公募自购权益类基金金额已达到21 亿元，机构用真金白银表达对市场长期价值的认可。 从新发市场来看，公募排排网数据显示，5月26日至6月1日，全市场合计有37只公募新基金启动募集， 数量创下近7周新高，且权益类基金占比超八成。 股票私募在经历4月上旬的"减仓潮"后，也逐步恢复理性。据私募排排网数据，截至5月16日，股票私募 整体仓位指数稳定在75.16%，连续6周坚守在75%上方。其中，百亿级私募仓位指数已连续2周上涨，并 且在时隔5周后，再次突破80%的仓位大关，展现出对市场机会的积极捕捉。 除公私募机构外，作为长线资金的保险资金，入市动态也备受关注。今年1月和3月，金融监管总局批复 开展保险资金长期投资第二批试点，规模共计1120亿元。5月，金融监管总局局长李云泽在国新办举行 的新闻发布会上表示，将进一步扩大保险资金长期投资试点范围，拟再批复600亿元， ...

值得注意的是，近期，多家卖方机构提出了"港股迎来价值重估"的观点，他们判断，后续，港股市场有 望迎来海内外增量资金。 恒生指数高开0.01%，恒生科技指数涨0.52%。快手涨超6%，小米集团涨超2%。 关于港股后市 据国泰君安国际策略团队统计，近一段时间，南向资金最主要净流入银行行业，大金融板块获得南向资 金的净流入规模超过165亿港元，而资讯科技行业则遭遇南向资金的净流出，规模超过205亿港元。 该策略团队进一步分析，资金在科技股获利了结，一方面是因为资本市场习惯性"买预期、卖现实"，另 一方面，关税前景仍然充满不确定性。 从估值角度看，财通证券首席策略分析师李美岑指出，2024年以来，南下资金涌入带动港股估值持续修 复，恒生指数PE从7.5倍左右震荡上行至当前10.5倍，与近十年均值水平相当，仍称不上贵，相较2018 年初、2021年初高位还有较大提升空间，港股的估值修复仍在路上。 此外，2025年也是港股IPO市场的大复苏之年，香港将为国内企业提供了募集外资的重要窗口，正在 2025年加速兑现，香港仍然是当之无愧的国际金融中心，也将在我国未来的资本市场发展中起到重要的 角色，今天的香港处在一个转型和过渡 ...

证券研究报告 | 2025年05月27日 杭州银行（600926.SH） 转债触发强赎，高成长优质行将迎价值重估 |  | 公司研究·公司快评 | |  | 银行·城商行Ⅱ | 投资评级：优于大市（维持）  | | --- | --- | --- | --- | --- | --- | | 证券分析师： | 田维韦 | 021-60875161 | | tianweiwei@guosen.com.cn | 执证编码：S0980520030002 | | 证券分析师： | 王剑 | 021-60875165 | | wangjian@guosen.com.cn | 执证编码：S0980518070002 | 事项： 2025 年 5 月 26 日晚间，杭州银行公告：公司股票自 2025 年 4 月 29 日至 2025 年 5 月 26 日期间已有 15 个交易日的收盘价不低于"杭银转债"当期转股价格 11.35 元/股的 130%（含 130%，即不低于 14.76 元/ 股），根据《杭州银行股份有限公司公开发行 A 股可转换公司债券募集说明书》的相关约定，已触发"杭 银转债"的有条件赎回条款。 评论： ...

Group 1 - The core viewpoint is that the innovative drug sector is experiencing a significant recovery in stock prices, attracting attention from brokers for research and investment opportunities [2] - The Tianhong Innovative Drug ETF (517380) has seen a net inflow of 3.6 million yuan, with a current scale of 389 million yuan as of May 26 [1] - The Tianhong ETF is the only product that comprehensively covers the innovative drug sector across A-shares and Hong Kong stocks, with a focus on the "Hengsheng Huasheng Hong Kong Innovative Drug Selected 50" index [1] Group 2 - The innovative drug industry is entering a new cycle of value reassessment due to a combination of policy, industry, and performance factors [2] - Longjiang Securities suggests that the previous valuation methods used during the bear market may no longer be applicable, indicating a need for a re-evaluation of the valuation system for innovative drug companies [2] - There has been significant interest from brokers, with nearly 60 companies in the pharmaceutical and biotechnology sector being researched this month, highlighting the sector's attractiveness [2]

纯债基金方面,一季度有12只FOF持仓景顺长城景泰裕利纯债,总持仓市值1.19亿。截至一季度末,该基金 规模达152亿元,过去三年的业绩排名均位列同类基金前列(数据来源:银河证券,截至2025年一季末,同类基 金为普通债券型基金(二级)(A类),具体排名分别为259/898、234/769、187/655)。其过去五年的历史最大 回撤仅为-2.14%,具有较好的回撤控制表现(数据来源:wind,截至2025.5.19)。 从主动权益到被动指数,从"固收+"到纯债,景顺长城均有基金产品入列公募FOF持仓数量和规模的TOP10, 受市场上的"专业买手"认可,也体现了景顺长城近年来通过多元化布局,在巩固股票投资优势的同时,朝 着"多资产管理专家"目标稳步迈进,在不同资产领域积累起投资实力。 资料显示,景顺长城品质长青基金经理农冰立和研究精选基金经理张雪薇,都是长期深耕科技成长领域的 基金经理,也是该公司科技军团中的得力干将。其中,农冰立对科技产业趋势理解深刻,投资中立足于中观 产业趋势研判,再做自下而上的个股精选,在近年科技行情中表现亮眼,截至2025年一季度,品质长青混合在 过去一年内回报达59.45%,同期基准 ...

据中国证券报，有基金公司分析称，随着部分创新药头部企业实现减亏或扭亏为盈，中国创新药行业或 迎来价值重估的关键转折点。同时，国家对创新药产业的支持力度不断加大，包括优化药品集采政策、 强化质量评估和监管等，这些都为创新药板块提供了积极的发展环境。 开源证券研报表示，2025年，医药产业创新发展全力推进，并明确提出优化药品集采，医药政策稳中向 好。同时，老龄化背景下未满足的临床需求快速增长、企业创新能力不断提升等长期产业趋势未曾变 化，后续随着创新药驱动制药板块新周期、医疗合规常态化及消费医疗逐步回暖，医药板块有望重回稳 定增长。展望2025年下半年，首选创新药，关注消费复苏。 5月26日，港股主要指数集体低开，医药生物板块小幅飘红，热门ETF中，港股创新药ETF（159567） 小幅高开，截至发稿涨超0.70%，成交额迅速突破3000万元，换手率超1.9%，盘初交投活跃。 成分股方面，东阳光长江药业涨近4%、金斯瑞生物科技、昭衍新药、先声药业、远大医药截至发稿涨 超2%，信达生物、泰格医药、君实生物、联邦制药等多股跟涨。 港股创新药ETF（159567）紧密跟踪港股通创新药指数（987018），该指数反映港股 ...

Group 1: Broker Research Focus - Since May, brokers have conducted research on over 670 listed companies, with high attention on sectors such as electronics, pharmaceuticals, and non-ferrous metals [1][4] - The electronics sector has been the most frequently researched, with over 90 companies being targeted, including Anji Technology and Huanxun Technology, which received attention from at least 25 brokers [3] - The pharmaceutical sector has also seen significant interest, with nearly 60 companies being researched, including Huadong Medicine and Sanyou Medical, with over 15 brokers involved in their investigations [4] Group 2: Military Industry Interest - The defense and military sector has experienced a surge in research interest, with over 20 companies being investigated since May, including Aerospace Nanhu and Xi'an Huada [6] - Aerospace Nanhu has reported a stock price increase of over 102% this year and has a backlog of orders worth 1.4 billion yuan [6][7] - Xi'an Huada has noted a positive recovery in defense sector demand since March, following a slow start to the year [6] Group 3: Stock Rating Adjustments - Since May, nearly 50 stocks have had their ratings adjusted, with 17 stocks being upgraded, including Sifang Co. and Weicai Technology [2][8] - For example, Tianfeng Securities upgraded Sifang Co. from "Hold" to "Buy" due to stable business development [9] - Conversely, over 30 stocks have seen their ratings downgraded, including Wentai Technology, which was downgraded from "Buy" to "Hold" due to changes in its main business structure [9]

东方财富Choice数据显示，5月以来，券商调研了670余家上市公司。本月券商关注量较高的上市公司集中 在电子、医药生物、有色金属等领域，此外国防军工板块的关注度也在近期大幅升高。 与此同时，券商对于股票的评级也在动态变化，5月份以来，近50只股票评级发生变化，其中不乏一些关注度 较高的股票。 券商扎堆调研电子、医药行业上市公司 电子成为近期券商最高频调研的行业，5月以来电子行业超90家上市公司被券商调研。其中，安集科技、闻泰 科技、深南电路、安克创新、希荻微、汉朔科技等公司均在本月被不少于25家券商扎堆调研。 例如，华东医药近期接待东方财富证券、国泰海通等30家券商调研。公司在调研中介绍，公司围绕肿瘤、内分 泌、自免三大领域加速布局产品管线，截至今年4月，公司创新药管线已超80项，其中自研项目近50项。阳光 诺和也在近期业绩说明会上表示，公司目前有数十项创新产品处于研发阶段，覆盖自免、疼痛管理、心内等多 个治疗领域。 长江证券近期研报称，当前创新药行业迎来政策、产业和业绩三因素共振，有望进入价值重估的新周期。过 去"熊市思维"下的估值方法可能已经不适用于当前，需要对创新药公司的估值体系进行重塑。 此外，有色 ...